Inhaled low-dose iloprost for pulmonary hypertension: A prospective, multicenter, open-label study

Clinical Cardiology

Volumn 35, Issue 6, 2012, Pages 365-370

  Sun, Yun Juan ^a   Xiong, Chang Ming ^a   Shan, Guang Liang ^b   Gu, Qing ^a   Zeng, Wei Jie ^c   Lu, Xian Ling ^d   Zhu, Feng ^a   Liu, Zhi Hong ^a   Ni, Xin Hai ^a   He, Jian Guo ^a  

^a FUWAI HOSPITAL   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^c JINAN UNIVERSITY   (China)

^d First Affiliated Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ILOPROST;

6 MINUTE WALK DISTANCE; ABDOMINAL DISTENSION; ADULT; ANOREXIA; ARTERIAL PRESSURE; ARTICLE; CHEST DISTRESS; CHINA; CLINICAL ASSESSMENT TOOL; CLINICAL PROTOCOL; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; FEMALE; FLUSHING; FOLLOW UP; FUNCTIONAL STATUS; HEADACHE; HEART HEMODYNAMICS; HEART INDEX; HEART OUTPUT; HUMAN; HYPOTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIXED VENOUS OXYGEN SATURATION; OPEN STUDY; OXYGEN SATURATION; PREMATURITY; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; SIDE EFFECT; SYSTEMIC ARTERIAL OXYGEN SATURATION; THORAX DISEASE; WORLD HEALTH ORGANIZATION;

EID: 84862189923     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.21987     Document Type: Article

References (28)

1. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34:1219-1263.
2. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation. 2004;109:159-165. (Pubitemid 38114133)
3. Galie N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med. 2003;2:123-137. (Pubitemid 37062722)
4. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327:70-75.
5. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159:1925-1932. (Pubitemid 29275065)
6. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-329. (Pubitemid 34815354)
7. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174:1257-1263. (Pubitemid 44924827)
8. Olschewski H, Walmrath D, Schermuly R, et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med. 1996;124:820-824. (Pubitemid 26128412)
9. Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med. 1999;160:600-607. (Pubitemid 29380679)
10. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000;342:1866-1870. (Pubitemid 30419050)
11. Olschewski H, Ghofrani HA, Schmehl T, et al; for the German PPH Study Group. Inhaled iloprost to treat severe pulmonary hypertension: an uncontrolled trial. Ann Intern Med. 2000;132:435-443. (Pubitemid 30149040)
12. Ivy DD, Doran AK, Smith KJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2008;51:161-169.
13. Kawald A, Burmester GR, Huscher D, et al. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study. J Rheumatol. 2008;35:1830-1837.
14. ATS statement: guidelines for the six-minutewalk test.Am J Respir Crit Care Med. 2002;166:111-117.
15. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-2157. (Pubitemid 41653106)
16. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension.N Engl J Med. 2002;346:896-903. (Pubitemid 34984638)
17. Jais X, D'Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFIT (Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52:2127-2134.
18. Machherndl S, Kneussl M, Baumgartner H, et al. Long-term treatment of pulmonary hypertension with aerosolized iloprost. Eur Respir J. 2001;17:8-13. (Pubitemid 32600550)
19. Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J. 2005;26:1895-1902. (Pubitemid 41253303)
20. Olschewski H, Hoeper MM, Behr J, et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med. 2010;104:731-740.
21. Ewert R, Wensel R, Opitz CF. Aerosolized iloprost for primary pulmonary hypertension. N Engl J Med. 2000;343:1421-1422.
22. Ewert R, Opitz C, Wensel R, et al. Iloprost as inhalational and intravenous long-term treatment of patients with primary pulmonary hypertension. Register of the Berlin Study Group for Pulmonary Hypertension [article in German]. Z Kardiol. 2000;89:987-999.
23. Reichenberger F, Mainwood A, Morrell NW, et al. Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension. Pulm Pharmacol Ther. 2011;24:169-173.
24. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119:2250-2294.
25. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115:343-349.
26. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106:1477-1482.
27. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780-788. (Pubitemid 34925627)
28. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 2003;42:158-164. (Pubitemid 36760778)